The albumin-to-alkaline phosphatase ratio as an independent predictor of future non-alcoholic fatty liver disease in a 5-year longitudinal cohort study of a non-obese Chinese population

Table 3 The effect size of AAPR on NAFLD in prespecified and exploratory subgroups in each subgroup

Characteristic	No. of participants	HR (95%CI)	P-value	P-interaction
Clinical baseline subgroup
Age (years)				0.1504
< 30	2016	0.80 (0.40, 1.61)	0.5334
≥ 30, < 45	4220	0.70 (0.47, 1.02)	0.0623
≥ 45, < 60	2740	0.37 (0.22, 0.63)	0.0002
≥ 60	1754	0.82 (0.42, 1.61)	0.5648
Sex				0.9157
Men	5891	0.61 (0.43, 0.88)	0.0073
Women	4839	0.63 (0.42, 0.94)	0.0252
BMI, kg/m²				0.0076
≤ 18.5	821	86.13 (5.86, 968.98)	0.0012
18.6–25	9909	0.60 (0.46, 0.79)	0.0003
SBP, mmHg				0.0292
< 140	9076	0.54 (0.40, 0.74)	0.0001
≥ 140	1657	0.94 (0.70, 1.28)	0.7140
DBP, mmHg				0.0003
< 90	9857	0.48 (0.35, 0.65)	< 0.0001
≥ 90	876	1.15 (0.89, 1.49)	0.2748
Liver function subgroup
GGT, U/L				0.8335
< 40	8977	0.63 (0.47, 0.84)	0.0016
≥ 40	1770	0.67 (0.41, 1.08)	0.0996
ALT, U/L				0.8653
< 40	10,109	0.61 (0.46, 0.81)	0.0008
≥ 40	640	0.57 (0.24, 1.34)	0.1948
AST, U/L				0.6524
< 40	10,419	0.69 (0.52, 0.90)	0.0063
≥ 40	330	0.48 (0.10, 2.32)	0.8708
Kidney function subgroup
Cr, mmol/L				0.0247
< 108	9809	0.23 (0.17, 0.30)	< 0.0001
≥ 104	937	1.37 (0.68, 2.76)	0.3732
Blood glucose metabolism subgroup
FPG, mmol/L				0.4721
< 6.1	9931	0.58 (0.43, 0.77)	0.0002
≥ 6.1	799	0.76 (0.38, 1.55)	0.4578
Lipid metabolism subgroup
TC, mmol/L				0.0059
< 5.2	8372	0.48 (0.35, 0.67)	< 0.0001
≥ 5.2	2358	0.93 (0.70, 1.23)	0.5994
TG, mmol/L				0.0155
< 1.7	8348	0.48 (0.33, 0.68)	< 0.0001
≥ 1.7	2382	0.88 (0.62, 1.25)	0.4658
HDL-C, mmol/L				0.0340
< 0.9	392	2.01 (0.63, 6.38)	0.2368
≥ 0.9	10,338	0.55 (0.45, 0.77)	< 0.0001

ISSN: 1476-511X